Page last updated: 2024-12-07

nsc-87877

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NSC-87877: potent Shp2 (nonreceptor protein tyrosine phosphatase) inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID92577
CHEMBL ID472004
CHEMBL ID1208151
CHEMBL ID1404918
CHEBI ID95064
SCHEMBL ID14154415
SCHEMBL ID13738901
SCHEMBL ID22494078
MeSH IDM0501040

Synonyms (47)

Synonym
5-quinolinesulfonic acid, 8-hydroxy-7-(6-sulfo-2-naphthylazo)-
56990-57-9
NSC87877 ,
8-hydroxy-7-[(e)-(6-sulfo-2-naphthyl)azo]quinoline-5-sulfonic acid
8-hydroxy-7-(6-sulfo-naphthalen-2-ylazo)-quinoline-5-sulfonic acid
NCI60_041943
8-hydroxy-7-((6-sulfo-2-naphthyl)diazenyl)-5-quinolinesulfonic acid
8-hydroxy-7-((6-sulfonaphthalen-2-yl) diazenyl)quinoline-5-sulfonic acid
nsc-87877
NCGC00013917 ,
NCI87877
NCISTRUC1_001562
NCISTRUC2_001738
NCGC00097026-01
bdbm50087879
CHEMBL472004 ,
nsc 87877
CCG-37311
NCGC00013917-02
8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid
8-hydroxy-7-[(6-sulfo-2-naphthyl)azo]-5-quinolinesulfonic acid
5-quinolinesulfonicacid, 8-hydroxy-7-[2-(6-sulfo-2-naphthalenyl)diazenyl]-
NCGC00346803-01
bdbm152210
smr004701746
MLS006010814
SCHEMBL14154415
CHEMBL1208151
AKOS024457197
SCHEMBL13738901
CHEMBL1404918
CHEBI:95064
NCGC00013917-09
8-oxo-7-[(6-sulfo-2-naphthalenyl)hydrazinylidene]-5-quinolinesulfonic acid
Q27166834
AS-16570
(e)-8-hydroxy-7-((6-sulfonaphthalen-2-yl)diazenyl)quinoline-5-sulfonic acid
HMS3742K15
CS-0014260
A899784
HY-18756
SCHEMBL22494078
NCGC00013917-08
8-hydroxy-7-[(6-sulfonaphthalen-2-yl)diazenyl]quinoline-5-sulfonic acid
DTXSID90866596
8-oxo-7-[2-(6-sulfonaphthalen-2-yl)hydrazinylidene]-7,8-dihydroquinoline-5-sulfonic acid
AKOS040742315

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID893
15-lipoxygenase, partialHomo sapiens (human)Potency3.16230.012610.691788.5700AID887
EWS/FLI fusion proteinHomo sapiens (human)Potency16.68130.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency2.23870.28189.721235.4813AID2326
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency3.16230.316212.765731.6228AID881
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency3.16230.00638.235039.8107AID881
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)IC50 (µMol)0.36000.29002.20754.2300AID1674081
Tyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)IC50 (µMol)0.31900.31804.00429.6000AID1206871; AID1674080; AID1866108; AID364912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (110)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
MAPK cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
hematopoietic progenitor cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of humoral immune response mediated by circulating immunoglobulinTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
G protein-coupled receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of angiogenesisTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
platelet formationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell costimulationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of mast cell activation involved in immune responseTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
megakaryocyte developmentTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of T cell proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
natural killer cell mediated cytotoxicityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of apoptotic processTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of MAPK cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of B cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
platelet aggregationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of inflammatory response to woundingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
epididymis developmentTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycleTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
intracellular signal transductionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
mitotic cell cycleTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
DNA damage checkpoint signalingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
triglyceride metabolic processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
axonogenesisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
brain developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
heart developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
hormone-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cerebellar cortex formationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
platelet formationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
T cell costimulationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of chondrocyte differentiationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of type I interferon productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
microvillus organizationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of interferon-beta productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
multicellular organism growthTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
organ growthTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
megakaryocyte developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
atrioventricular canal developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
ERBB signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
hormone metabolic processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
glucose homeostasisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of protein-containing complex assemblyTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of ossificationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of mitotic cell cycleTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of glucose importTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of insulin secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of protein export from nucleusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of hormone secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
neurotrophin TRK receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
multicellular organismal reproductive processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
genitalia developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
inner ear developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
homeostasis of number of cells within a tissueTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of cortisol secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
Bergmann glial cell differentiationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of growth hormone secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
face morphogenesisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
intestinal epithelial cell migrationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cellular response to epidermal growth factor stimulusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
MAPK cascadeDual specificity protein phosphatase 5Homo sapiens (human)
protein dephosphorylationDual specificity protein phosphatase 5Homo sapiens (human)
dephosphorylationDual specificity protein phosphatase 5Homo sapiens (human)
peptidyl-tyrosine dephosphorylationDual specificity protein phosphatase 5Homo sapiens (human)
peptidyl-threonine dephosphorylationDual specificity protein phosphatase 5Homo sapiens (human)
ERK1 and ERK2 cascadeDual specificity protein phosphatase 5Homo sapiens (human)
endoderm formationDual specificity protein phosphatase 5Homo sapiens (human)
negative regulation of MAPK cascadeDual specificity protein phosphatase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
transmembrane receptor protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
SH2 domain bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell adhesion molecule bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
phosphorylation-dependent protein bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
phosphoprotein phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
signaling receptor complex adaptor activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cell adhesion molecule bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
peptide hormone receptor bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
molecular adaptor activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
protein bindingDual specificity protein phosphatase 5Homo sapiens (human)
protein tyrosine/serine/threonine phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
myosin phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
MAP kinase tyrosine phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
protein tyrosine/threonine phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
MAP kinase tyrosine/serine/threonine phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
extracellular regionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleolusTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell-cell junctionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
membraneTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
specific granule lumenTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
extracellular exosomeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
tertiary granule lumenTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
alpha-beta T cell receptor complexTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
nucleoplasmDual specificity protein phosphatase 5Homo sapiens (human)
cytoplasmDual specificity protein phosphatase 5Homo sapiens (human)
nucleusDual specificity protein phosphatase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (53)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1674080Inhibition of human SHP2 catalytic domain (205 to 593 residues) expressed in Escherichia coli DH5alpha using 6,8-difluoro-4-methylumbelliferyl phosphate as substrate incubated for 30 mins by fluorescence method2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
AID675316Binding affinity to human proadrenomedullin N-terminal 20 peptide assessed as fragmentation of PAMP protein at 500 uM by MS analysis2012European journal of medicinal chemistry, Sep, Volume: 55Identification of first proadrenomedullin N-terminal 20 peptide (PAMP) modulator by means of virtual screening and NMR interaction experiments.
AID675314Binding affinity to human synthetic proadrenomedullin N-terminal 20 peptide assessed as reduction in absorbance at 1 uM after 1 hr by monoclonal antibody method2012European journal of medicinal chemistry, Sep, Volume: 55Identification of first proadrenomedullin N-terminal 20 peptide (PAMP) modulator by means of virtual screening and NMR interaction experiments.
AID1206871Inhibition of human recombinant GST-tagged SHP2 (205 to 593) expressed in Escherichia coli DH5-alpha using DiFMUP as substrate after 30 mins by fluorescence assay2015Bioorganic & medicinal chemistry, Jun-15, Volume: 23, Issue:12
Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.
AID675315Binding affinity to human proadrenomedullin N-terminal 20 peptide at 500 uM by NMR spectroscopy2012European journal of medicinal chemistry, Sep, Volume: 55Identification of first proadrenomedullin N-terminal 20 peptide (PAMP) modulator by means of virtual screening and NMR interaction experiments.
AID364912Inhibition of SHP2 using 6,8-difluoro-4-methylumbelliferyl phosphate as substrate2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.
AID1674081Inhibition of human SHP1 catalytic domain (205 to 597 residues) expressed in Escherichia coli DH5alpha using 6,8-difluoro-4-methylumbelliferyl phosphate as substrate incubated for 30 mins by fluorescence method2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
AID1866108Inhibition of SHP2 (unknown origin)2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (17.50)29.6817
2010's24 (60.00)24.3611
2020's9 (22.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.57 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (7.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (92.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]